Pulmatrix Sets October 16 Vote on Eos SENOLYTIX Reverse Merger, Updates Exchange Ratio to 8.55
PULM sits 24% above its 52-week low of $1.16 on light trading volume (0.3× avg).
Summary
Pulmatrix's amended S-4 sets an October 16, 2026 shareholder vote on its reverse merger with Eos SENOLYTIX, updates the exchange ratio to 8.55, and discloses new financing details including the $1 million Series B Preferred Stock closing and $2.5 million in bridge funding.
Key Events · M&A and Partnerships · PULM
-
Special Meeting Set for October 16
Pulmatrix will hold its special meeting of stockholders on October 16, 2026 at 8:30 a.m. Eastern Time to vote on the reverse merger with Eos SENOLYTIX, moving from the previously disclosed October 2, 2026 date.
-
Exchange Ratio Updated to 8.55
Each share of Eos capital stock is estimated to receive approximately 8.55 shares of Pulmatrix common stock, based on capitalization as of August 28, 2026, subject to adjustment for changes in outstanding securities.
-
Legacy Holders to Own 6%
Pulmatrix securityholders as of immediately prior to the merger are expected to own approximately 6% of the combined company on a fully-diluted basis, with Eos securityholders owning the remaining 94%.
-
CEO RSUs Granted for 13M Shares
Eos issued restricted stock units to RCM Eos RSU HOLDINGS, LLC on July 7, 2026 for up to the equivalent of 13,000,000 shares of Pulmatrix common stock, vesting upon achievement of four clinical milestones.
Analysis · PULM · Life Sciences
Pulmatrix's Amendment No. 3 to its S-4 moves the shareholder vote on its reverse merger with Eos SENOLYTIX to October 16, 2026, and updates the exchange ratio to approximately 8.55 shares of Pulmatrix common stock per share of Eos capital stock. The filing also discloses that the CEO RSUs were granted on July 7, 2026 for up to 13 million shares, the Backstop Financing Agreement was amended and restated with $2.5 million in initial bridge funding, and the Pulmatrix Financing closed on April 16, 2026 with $1 million in gross proceeds. Legacy Pulmatrix holders will own approximately 6% of the combined company, with Eos securityholders owning the remaining 94%. The merger remains the company's only clear path to survival given its going concern warning and $2.2 million cash balance as of June 30, 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PULM was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.16 to $5.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.